

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

(U.S. APPLICATION NO (If known,

(see 37 C.F.R.1.5)

(09/319678

INTERNATIONAL APPLICATION NO

PCT/EP97/06907

INTERNATIONAL FILING DATE

10 DECEMBER 1997

[EARLIEST] PRIORITY DATE CLAIMED

11 DECEMBER 1996

TITLE OF INVENTION

NONHELICAL SUPRAMOLECULAR NANOSYSTEMS

APPLICANTS FOR DO/EO/US

**Albert ESCHENMOSER, Christian MICULKA, Norbert WINDHAB,
Hans-Ulrich HOPPE**

Applicants herewith submit to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)), including 4 sheets of formal drawings and a copy of the International Search Report.
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventors (35 U.S.C. 371(c)(4)).
10. ☐ The annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:
 PCT/IPEA/416, PCT/IB/306
 PCT/ISA/210, PCT/RO/101
 Check No. 05782 \$1,244.00
 Amendments Under PCT Article 34

EXPRESS MAIL

MAILING LABEL NUMBER EL228911342USDATE OF DEPOSIT June 9, 1999

I hereby certify that this paper or fee is being
deposited with the United States Postal Service

"Express Mail Post Office to Addressee"
to Addressee" service under 37 CFR 1.10
on the date indicated above and is

addressed to: BOX PCT,
COMMISSIONER OF PATENTS AND TRADEMARKS,
WASHINGTON, D.C. 20231

Charles J. Smith

(Typed name of person mailing paper or fee)

09 JUN 1999 09:16:00

09 JUN 1999

09/319678

17. ☒ The following fees are submitted:

(CALCULATIONS /PTO USE ONLY)

Basic National Fee (37 CFR 1.492(a)(1)-(5):

Search Report has been prepared by the EPO or JPO.....\$840.00(\$ 840.00

International preliminary examination fee paid to USPTO (37 CFR 1.482) (.....\$700.00 (

No international preliminary examination fee paid to USPTO (37 CFR 1.482) (but international search fee paid to USPTO (37 CFR 1.445(a)(2))...\$770.00(

Neither international preliminary examination fee (37 CFR 1.482) nor (international search fee (37CFR 1.445(a)(2)) paid to USPTO.....\$1040.00 (

International preliminary examination fee paid to USPTO (37 CFR 1.482) (and all claims satisfied provisions of PCT Article 33(2)-(4).....\$96.00 (

ENTER APPROPRIATE BASIC FEE AMOUNT = (\$ 840.00 /

Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐20 ☐30 (\$ / months from the earliest claimed priority date (37 CFR 1.492(e)).28 Claims /Number Filed / Number Extra /Rate (Total Claims / 28 - 20 = / 8 /X \$18.00 (\$ 144.00 /Independent Claims / 1 - 3 = / 0 /X \$78.00 (\$ 000.00 /

Multiple dependent claim(s) (if applicable) /+ \$260.00 (\$ 260.00 /

TOTAL OF ABOVE CALCULATIONS = (\$1,244.00 /

Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity (/ statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28). (/

SUBTOTAL = (\$1,244.00 /Processing fee of **\$130.00** for furnishing the English translation later than (/ ☐20 ☐30 months from the earliest claimed priority date (37 CFR 1.492(f)).+ (\$ /**TOTAL NATIONAL FEE =** (\$1,244.00 /Fee for recording the enclosed assignments (37 CFR 1.21(h)). The assignment (/ must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) **\$40.00** per property + (\$ 0.00 /**TOTAL FEES ENCLOSED =** (\$1,244.00 /

(Amount to be: /

(refunded /\$

(charged /\$

a. ☒ Our check in the amount of **\$1,244.00** to cover the above fees is enclosed.b. ☐ Please charge my Deposit Account No. 50-0320 in the amount of \$_____ to cover the above fees.

A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0320. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

WILLIAM F. LAWRENCE
FROMMER LAWRENCE & HAUG LLP
745 FIFTH AVENUE
NEW YORK, NEW YORK 10151

SIGNATURE

WILLIAM F. LAWRENCE

NAME

28,029

REGISTRATION NUMBER

Dated: **JUNE 9, 1999**

09319678-061699

09/319678

80 Rec'd PCT/PTO 09 JUN 1999

PATENT
514485-3729

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : ESCHENMOSER et al.
U.S. Serial No. :
Priority Appln. : PCT/EP97/06907
Priority Filing Date : 10 December 1997
For : NONHELICAL SUPRAMOLECULAR
NANOSYSTEMS


745 Fifth Avenue
New York, NY 10151
June 9, 1999

EXPRESS MAIL

Mailing label number EL228911342US

Date of Deposit June 9, 1999

I hereby certify that this paper or fee is being
deposited with the United States Postal Service
"Express Mail Post Office to Addressee" service
under 37 CFR 1.10 on the date indicated above
and is addressed to Assistant Commissioner for
Patents, Washington, D.C. 20231


(Typed name of person mailing paper or fee)


(Signature of person mailing paper or fee)

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231


ATTN: Box Patent Application

Sir:


Preliminary to the examination of this U.S. National
Phase application, please enter the following amendments:

09/319678

Page 10, lines 15 to 25, replace the structural formula shown with the following structural formula:



Page 11, between lines 10 and 15, replace the reaction scheme shown with the following reaction scheme:



IN THE CLAIMS:

21. (Amended) A supramolecular nanosystem as claimed in [claim 1, wherein] any of claims 1 to 16, where an oligomer A is linked to oligomer B after association.


REMARKS

The figures on pages 10 and 11 were amended so that they are enlarged. These figures were amended in the PCT application and appear on pages 10a and 11a. These pages are attached to the International Search Report.

Entry of this amendment and an early examination on the merits are respectfully solicited.

Respectfully submitted,
FROMMER LAWRENCE & HAUG LLP

Attorneys for Applicant

By 
William F. Lawrence
Reg. No. 28,029
Tel. (212) 588-0800

WFL\jm

Hoechst Aktiengesellschaft

H26304PC BÖ/ZW

5

Nonhelical supramolecular nanosystems

The present invention relates to a supramolecular nanosystem which comprises at least one essentially nonhelical oligomer (oligomer A) and one or more, identical or different, essentially nonhelical and mutually nonpairing oligomers with identical or different functional units (oligomer B), where oligomer A can undergo specific noncovalent pairing with oligomer B, and oligomer B can be determined through its monomers.

The miniaturization of technical components is now advancing into the area where sizes are of molecular magnitude. The production of miniaturized, integrated electronic circuits by conventional processes such as, for example, by photochemical treatment of a component is also determined by the particular chemical and physical properties of the materials used. In the nanometer region it is possible to utilize the discrete molecular or atomic-quantized material properties in order to produce novel components.

The material properties generated or influenced by nanostructuring are, in particular, optical or chiroptical properties, for example in Kerr cells and in the LEP technique; electrical properties, for example in semiconductors or conductors through constitution of conduction bands, positive holes, color centers or regions with tunneling currents which can be modulated; chemical catalytic properties such as, for example, with zeolites, metal cluster catalysis, constitution of reaction spaces; and physical surface and transport properties such as permeability, adhesion and compatibility with other materials or sensitive biological systems (biocompatibility).

In supramolecular chemistry, the nanomolecular properties described are utilized specifically to produce novel materials able to organize themselves in the form of pairing systems.

Pairing systems are supramolecular systems of noncovalent interaction which are distinguished by selectivity, stability and reversibility, and the properties thereof are preferably influenced thermodynamically, i.e., for

example, by temperature, pH and concentration. DNA and RNA play a fundamental role in this as carriers of genetic traits. However, it is also possible to use such pairing systems, for example because of their selective properties, as "molecular adhesive" for bringing together different metal clusters to give cluster assemblies with potentially novel properties [Mirkin, C. A. et al., *Nature*, 1996, 382, 607-9; Alivisatos, A. P. et al., *Nature*, 1996, 382, 609-11]. The pairing or hybridization properties of naturally occurring DNA have been used, for example, to bring about the pairing of metal clusters bound to DNA strands with a complementary DNA strand. This resulted in cluster assemblies with potentially novel material properties. Supramolecular nanosystems of these types can therefore be regarded as "molecular machines" or functional "molecular circuits".

Strong and thermodynamically controllable pairing systems are playing an increasingly important part for use in the area of nanotechnology for producing novel materials, diagnostic aids, therapeutic agents and microelectronic, photonic and optoelectronic components and for the controlled bringing together of molecular species to give supramolecular units.

However, DNA and RNA building blocks have the following disadvantages for producing pairing systems of these types:

- a) The forces holding two strands together, in particular hydrogen bonds and stacking effects, are very small by their nature. Such duplexes therefore have low stability. This can easily be established by recording a so-called transition plot and determining the transition point. Consequently, relatively long single strands are needed to produce pairing systems, which results in the content of the pairing system predominating in the supramolecular unit, i.e. the "nucleotide load" is large.
- b) The selectivity decreases owing to the formation of *Hoogsteen* pairings which are a possible alternative to *Watson-Crick* pairings. This is often associated with parallel duplexes or irreversible pairing processes.
- c) The high flexibility of the sugar-phosphate backbone leads to formation of helical conformations, which means that the spatial arrangement in supramolecular units can be controlled less well.

d) A possible interference with the genetic material of biological systems cannot be precluded if the supramolecular units are employed in a biological system, i.e. there is no orthogonality of the pairing process.

5 This means that the use of DNA or RNA building blocks for example in two- and three-dimensional supramolecular structures with complementary binding (see, for example, WO96/13522) in a physiological medium is possible only with difficulty, in particular in view of item d).

10 It was therefore an object of the present invention to find a system which avoids one or more of the described disadvantages as far as possible.

It has now been found, surprisingly, that essentially nonhelical supramolecular nanosystems represent particularly advantageous building
15 blocks.

The present invention therefore relates firstly to a supramolecular nanosystem which comprises at least one essentially nonhelical oligomer (oligomer A) and one or more, identical or different, essentially nonhelical
20 and mutually nonpairing oligomers with identical or different functional units (oligomer B), where oligomer A can undergo specific noncovalent pairing with oligomer B, and oligomer B can be determined through its monomers.

Noncovalent pairing means for the purpose of the present invention an
25 association of oligomer A with oligomer B via noncovalent interactions such as, for example, hydrogen bonds, salt links, stacking, metal ligands, charge transfer complexes and hydrophobic interactions.

The meaning of "can be determined" for the purpose of the present
30 invention is that the functional unit is addressed, i.e. encoded, by the oligomer. The code is defined by the previously established sequence and nature of the monomers. This can be, for example, a particular nucleotide sequence.

35 The nature and sequence of the monomers of oligomer B determines the nature and sequence of the monomers of oligomer A. In the case of nucleotides, these are the mutually complementary nucleotides (see, for example, Figure 2).

In a particular embodiment, oligomer A is able to pair both with oligomer B and with itself in the form of a hairpin loop. Depending on the external conditions, this can make it possible easily to induce and determine structural changes macroscopically (see, for example, Figure 4). For example, it is possible to cause structural changes in the molecular nanosystem according to the invention by changing the equilibrium conditions such as, for example, concentration of oligomer B, salt concentration, pH, pressure and/or temperature. It is also possible by adjusting particular equilibrium conditions to bring about pairing or unpairing of various regions so that initially remote residues in the molecule can be brought reversibly into direct vicinity (so-called nanotransport).

In a preferred embodiment, the essentially nonhelical oligomer is a pentopyranosyl-nucleic acid, in particular a ribo-, arabino-, lyxo- and/or xylo-pyranosyl-nucleic acid, preferably a ribopyranosyl-nucleic acid also called pyranosyl-RNA (p-RNA).

The p-RNA as an example of a pentopyranosyl-nucleic acid is a nucleic acid which, in place of the ribofuranose of RNA, contains the ribopyranose as sugar building block and therefore forms exclusively *Watson-Crick*-paired, antiparallel, reversibly "melting", *quasi*-linear and stable duplexes. In addition there are also homochiral p-RNA strands of opposite handedness which likewise pair in a controllable manner and are not strictly helical in the duplex formed. This specificity, which is valuable for constructing supramolecular units, is connected with the relatively low flexibility of the ribopyranose phosphate backbone and with the large inclination of the base plane relative to the strand axis and the tendency, resulting therefrom, to intercatenary base stacking in the resulting duplex, and can be attributed to the participation of a 2',4'-cis-disubstituted ribopyranose ring in the structure of the backbone. Because of the high selectivity and stability and the formation of strictly planar linear duplex strands, the pentopyranosyl-nucleic acid and, preferably, the p-RNA is particularly preferred for the present invention. All residues bound in the same way to the pentopyranosyl strand are located on the same side of the duplex, which is particularly advantageous. Pentopyranosyl-nucleic acids can be prepared, for example, as described by Eschenmoser et al. (Helv. Chim. Acta 1993, 76, 2161; Helv. Chim Acta 1995, 78, 1621; Angew. Chem. 1996, 108, 1619-1623) and generally have the D or L configuration.

The natural model for the preparation of the supramolecular nanosystem according to the invention is the decoding of amino acids for protein synthesis by the relevant base triplets as anticodon (see Figure 1). In analogy to this, according to the present invention identical or different functional units are bound to an oligomer of a defined structure. For example, a pentopyranosyl-oligonucleotide which is modified at the 3' and/or 5' end with free sulfhydryl groups is bound to monomaleimido-derivatized gold particles (in analogy to Alivisatos, A.P. et al. (1996), supra). The oligomer modified in this way (called oligomer B) is brought into contact for pairing with an oligomer A complementary thereto, so that the supramolecular nanosystem according to the invention can form. The duplex strands which form are generally in an essentially planar linear form, which is particularly advantageous.

Oligomer A is generally longer than oligomer B. A particularly preferred length of oligomer A is from about 10 to about 500, preferably from about 10 to about 100, monomer units. Oligomer B is generally about 4 to about 50, preferably about 4 to 25, in particular about 4 to about 15, especially about 4 to about 8, monomer units long.

In another embodiment, the pentopyranosyl part of the pentopyranosyl-nucleic acid can be modified in the form of a thiophosphate, alkylated phosphate, phosphonate and/or amide (see, for example, Uhlmann E. and Peyman A. (1990) Chemical Reviews, 90, 543-584, No. 4). In another embodiment of the present invention, one of the canonical nucleobases adenosine, guanosine, cytosine, thymidine and/or uracil or else isoguanosine, isocytosine, 2,6-diaminopurine and/or xanthine is used for coding the oligomers. In the last-mentioned cases, the complementary bases are present in the form of isoguanine/isocytosine or 2,6-diaminopurine/xanthine pairs. Otherwise, generally adenosine pairs with thymidine or uracil and guanosine pairs with cytosine.

In another embodiment, the noncovalent pairing between oligomer A and oligomer B can take place via a chelating agent. In this case for example the nucleobases of a pentopyranosyl-nucleic acid are replaced by the chelating agent. Examples of chelating agents suitable for this purpose are those derived from pyrazolylpyridine or pyridoquinazoline. In the presence of a metal ion, for example Cu^{2+} or Ni^{2+} , complexation takes place, and thus specific pairing between the two oligomers (see Figure 3).

The functional unit generally suitable for oligomer B is a metal, preferably a metal cluster, in particular a noble metal, especially gold, silver and/or platinum. Semiconductor compounds are also suitable, such as, for example, cadmium selenide and/or cadmium sulfide. Also suitable as functional unit is a peptide which can be bound to the oligomer via a suitable linker, for example N-phthaloylaminoethyluracil or N-phthaloyltryptamine. Another functional unit is, for example, a redox center, i.e. an electron donor or acceptor, for example a quinone or hydroquinone. Fluorescent labels, for example fluorophores, and/or chromophores such as, for example, benzoquinones or azobenzenes are also suitable. Other functional units may represent a chelating agent which is preferably derived from anthocyanins, polyoxycarboxylic acids, polyamines, dimethylglyoxime, ethylenediaminetetraacetic acid and/or nitrilotriacetic acid, or else conducting oligomers such as, for example, conjugated alkyne-alkene-aromatic compounds. The linkage of an oligomer to a functional unit which results in the oligomer B can in general be carried out using linkers known to the skilled worker (see, for example, Mirkin C.A. et al. (1996), *Nature*, 382, 607-609; Alivisatos, A.P. et al. (1996), *supra*; Dawson, P.E. et al. (1994), *S.B.H. Kent Science*, 30, 776-779; Liu C.-F. et al. (1996), 116, 4149-4153) or using purchasable base and amidite linkers (Wei Z. et al. *Bioconjugate Chem.* (1994), 5, 468-474; Liu C.-F. et al. (1991), *Proc. Natl. Acad. Sci. USA*, 91, 6584-6588). The oligonucleotides themselves can be prepared, for example, automatically in an oligonucleotide synthesizer.

In another embodiment, oligomer A can be linked, i.e. fixed, with oligomer B after the association. Chemical fixation is preferred, for example a covalent crosslinking, metathesis, Heck coupling, Michael addition of thiols and/or oxidative formation of disulfide bridges. It is particularly preferred for the supramolecular nanosystem according to the invention to be absorbed on a solid phase, for example a so-called wafer or support.

Examples of suitable support materials are ceramics, metal, in particular noble metal such as gold, silver or platinum, glasses, plastics, crystalline materials or thin layers of the support, in particular of said materials, or (bio)molecular filaments such as cellulose or scleroproteins.

Attachment to the support generally takes place covalently, quasi-covalently, supramolecularly or physically such as magnetically (Shepard, A.R. (1997) *Nucleic Acids Res.*, 25, 3183-3185, No. 15), in an electric field or through a molecular sieve. For example, oligomer A can be
5 either synthesized directly in position on the support or be linked to particular positions on the support. Examples are conjugation and attachment methods via periodate oxidation and reductive amination of the Schiff's base, N-hydroxysuccinimide esters of, preferably, dicarboxylic acid linker, ethylenediaminephosphoramidate linker, mercapto, iodoacetyl or
10 maleimido methods and/or covalent or noncovalent biotin linker methods.

Another embodiment of the present invention is a library comprising a plurality of different supramolecular nanosystems according to the invention. It is particularly advantageous for the library to be constructed by
15 combinatorial methods. A library constructed by combinatorial methods is suitable, for example, for screening for properties by pairing a (sub)library prepared randomly or by combinatorial deconvolution techniques with the complementary oligonucleotide (see, for example, Wilson-Lingardo (1996) *J. med. Chem.*, 39, 2720-2726).

20 In the case where the functional unit of oligomer B is, for example, a metal cluster, a library produced combinatorially is particularly suitable for searching for catalysts. For this purpose, for example, oligomer A is synthesized combinatorially and paired with a plurality of different
25 oligomers B with different metal clusters as functional units. This results in a so-called cluster library whose diversity correlates directly with that of oligomer A. Suitable and preferred for this are sublibrary routines which allow simple identification of the active species, such as, for example, positional scanning or orthogonal libraries. The cluster library can
30 subsequently be examined for its homogeneous catalytic properties for example in water for vinyl acetate monomer catalysis.

It is advantageous in general and particularly for producing libraries if the pentopyranosyl-nucleic acid has a relatively high cytosine and guanosine
35 content because, owing to the higher enthalpy of binding of this nucleotide pair compared with adenosine and thymidine, shorter oligonucleotides can be used, which makes it possible to reduce the "nucleotide load" in the supramolecular nanosystem according to the invention.

Replacement of the nucleobases by one or more identical or different chelating agents as described in detail above is able to reduce the "nucleotide load" further. This results in formation of one-center complexes which form linear, nonhelical, oligomeric metal complexes. Because of the arrangement like branches in one plane, the pairing process can react optimally to the size of the different metal centers. The duplexes formed in this way generally have an inclined, but nonhelical, repetitive structure, coordinates specific metal centers depending on the choice of the ligand, and makes metal-metal interactions or desired defects possible along the duplex axis. This makes it possible to produce in a controlled manner metal sequences which represent a novel nanoalloying kit for producing so-called "nanowires".

It is also possible with the supramolecular nanosystems according to the invention described above for example to spatially position different metal clusters on the supramolecular plane with a view to constructing electronic switching patterns (see, for example, Andres R.P. (1996) Science, 272, 1323-1325). It is also possible to construct so-called cluster lattices with rod-shaped dithiols, which show good stability (see, for example, Andres R.P. et al. (1996) Science, 273, 1690-1693; Schiffrin D.J. et al. (1995) Adv. Mat., 7, 795-797).

The described supramolecular nanosystem according to the invention has particularly high stability and selectivity and is particularly suitable for self-organization. In addition, it has controllable topicity and the aggregation or self-organization can be dynamically influenced particularly well.

Areas of application are therefore in particular the production of electronic components such as, for example, information storage media, diagnostic probes or photoelectronic components; catalysts; semiconductors; photochemical units; biocompatible materials or units or functional microprostheses.

The following figures and examples are intended to illustrate the invention in detail without restricting it thereto.

Description of the figures:

- Fig. 1: Diagrammatic representation of the natural base pairing in peptide synthesis
- 5 Fig. 2: Diagrammatic representation of a supramolecular nanosystem according to the invention with the nucleobases adenosine (A) and thymidine (T) and various functional units designated XI to XI (coding units).
- 10 Fig. 3: Diagrammatic representation of a one-center chelate complex with a pyrido[3,2-h]quinazolin-2(1)-one as chelating agent.
- Fig. 4: Diagrammatic representation of an equilibrium reaction between a hairpin loop and a duplex.
- Fig. 5: Section of an x-ray structure analysis of a nickel chelate-ribose-pyranose-pyrazolylpyridine complex

15

Examples


1. Preparation of a gold cluster-pyranosyl-RNA
- 20 Pyranosyl-RNA was prepared by the method of Eschenmoser et al. (supra) by a phosphoramidite synthesis. Gold clusters were bound to one strand as described in Mirkin C.A. et al. (1996), supra. The complementary strands were paired in a buffer solution (1 M NaCl, 10 mM Tris-HCl, pH 7) at 0°C (see Fig. 2).
- 25
2. Preparation of a self-complementary oligonucleotide with the sequence ITGGCCA
- The automatic solid-phase synthesis of the oligonucleotide with the
- 30 sequence ITGGCCA was carried out as described by Pitsch S. et al. (1993) *Helv. Chim. Acta* 78, 1621-1635. The average yield in an Eppendorf Ecosyn D300+ automatic synthesizer was 93.2%. The coupling times were 45 min, the oxidation time was 2 min and the detritylation times were 7 min with dichloroacetic acid flowing through. After the synthesis, the
- 35 oligonucleotide was deprotected with tetrakis(triphenyl)phosphinepalladium (20 mg for a 1 µmol batch of support) with the addition of 20 mg of diethylammonium bicarbonate and 20 mg of triphenylphosphine at room temperature for five hours, then washed with acetone and water and treated with fresh aqueous sodium dithiocarbamate solution for 45 min. The

product was then cleaved off by a 24% strength hydrazine hydrate solution at 4°C, rotating for 24 hours. Salts were removed in a reverse phase Sep-Pak cartridge, and purification was carried out by RP-HPLC (RP-18, water/acetonitrile gradient, pH 7). Salts were then removed again, and lyophilization resulted in the "trityl-on" product. This was deprotected with 80% strength formic acid, evaporated, taken up in 10 ml of water, extracted with dichloromethane and again purified by HPLC. 8 OD of the required product were obtained.

Examination by mass spectrometry gave the following result:

Samples: LX626-1: MS-No.: 970523

Objective: Characterization of the sample by mass spectrometry



Mass spectrometer: TSQ 700 (Finnigan/MAT)

Measuring conditions: MS; injection pump

Ionization: Electrospray ionization (ESI)

Results: The mass spectrum shows a molecular mass $M = 2242$

3. Molecular nanokinematics

The phosphoramidite method was used to synthesize a pyranosyl-RNA strand which was partly self-complementary as hairpin and had 4' and 5' linker ends with the sequence linker-pr-GCGA₅CGC-linker, and the linker ends were linked to maleimido-gold clusters as described by Alivisatos, A.P. et al. (1996), *supra*. Then the pairing of 10 mM product to the hairpin was detected by spectroscopy in standard buffer (0.15 M NaCl or 1 M NaCl, 10 mM Tris HCl, pH 7). Addition of one equivalent of the

Amended

Identical Text
to 10 but larger
80 Rec'd PCT/PTO 09 JUN 1999


- 10a -

Fig.

- 5 Die massenspektrometrische Untersuchung ergab folgendes Ergebnis:

Proben: LX626-1: MS-Nr.: 970523

Aufgabenstellung: Massenspektrometrische Charakterisierung der Probe



10

Massenspektrometer: TSQ 700 (Finnigan/MAT)

Meßbedingungen: MS; Spritzenpumpe

Ionisierung: Electrospray ionization (ESI)

Ergebnisse: Das Massenspektrum zeigt eine Molmasse $M = 2242$.


15

complementary strand pr-G(T₅)C proved by spectroscopy the opening of the hairpin and the separating of the gold clusters. The hairpin structure was restored simply by diluting the solution. It is possible in this way to expose a substrate to different reaction centers macroscopically in a controlled manner via the dilution (see Fig. 4).


4. Synthesis of a p-RNA-pyridylpyrazole ligand as monomer for oligomeric ligands
- 10 The following reaction scheme shows the preparation of the 2-[1-(2',3',4'-tri-O-benzoyl-1'β-ribofuranosyl)-3-pyrazolyl]pyridine:

Preparation of

2-[1-(2',3',4'-tri-O-benzoyl-1'β-ribofuranosyl)-3-pyrazolyl]pyridine



15




20

- 0.50 g (3.44 mmol) of 2-[3(5)-pyrazolyl]pyridine was dissolved in 30 ml of CH_2Cl_2 and cooled to -15°C . 2.30 g of 2',3',4'-tri-O-benzoyl-1'-D-ribofuranosyl trichloroacetimidate in 15 ml of CH_2Cl_2 were slowly added dropwise. The solution became pale yellow. Then 0.8 ml (1.2 equivalents)

Amended Fig.

Darstellung des 2-[7-(2',3',4'-tri-O-benzoyl-1'- β -ribofuranose)Pyrazol-9-yl]pyridin



of TMSOTf in 15 ml of CH_2Cl_2 was added dropwise at -15°C over the course of 15 minutes. The solution became cloudy, and a white precipitate formed. The solution was then stirred at between -10°C and $+5^\circ\text{C}$ for 5 hours. The solution was then filtered and concentrated. The product was purified by flash chromatography on silica gel ($\text{CH}_2\text{Cl}_2/\text{acetone}$: 95/5); 1.77 g (3 mmol, 87%) of product.

Rf : 0.47 ($\text{CH}_2\text{Cl}_2/\text{acetone}$: 9/1)

10 **Melting point** : 91 - 93°C ($\text{CH}_2\text{Cl}_2/\text{isohexane}$).

UV (CH_3CN) : λ = 202 nm ϵ = 21522
 λ = 230 nm ϵ = 35826
 λ = 274 nm ϵ = 7696

15 **^1H NMR** : δ (ppm) = 8.60 (dm, $J=4.8$ Hz, 1H, 6-H); 8.07 (d, $J=8.5$ Hz, 2H, 2*o-benz.-2'); 7.98 (d, $J=7.8$ Hz, 1H, H-3); 7.93 (d, $J=8.3$ Hz, 2H, 2*o-benz.-3' or 4'); 7.82 (d, $J=8.3$ Hz, 2H, 2*o-benz.-3' or 4'); 7.77 (d, $J=2.6$ Hz, 1H, H-11); 7.70 (td, $J=7.6$ and 1.8 Hz, 1H, H-4); 7.62 (t, $J=7.5$ Hz, 1H, p-benz.-4'); 7.52 (t, $J=7.5$ Hz, 1H, p-benz.-3'); 7.48 (t, $J=7.5$ Hz, 2H, 2*m-benz.-4'); 7.46 (t, $J=7.5$ Hz, 1H, p-benz.-2'); 7.34 (t, $J=7.8$ Hz, 2H, 2*m-benz.-3'); 7.25 (t, $J=7.7$ Hz, 2H, 2*m-benz.-2'); 7.19 (ddd, $J=7.6$, 4.8 and 1.8 Hz, 1H, H-5); 6.99 (d, $J=2.6$ Hz, 1H, H-10); 6.49 (t, $J=3.1$ Hz, 1H, H-3'); 6.17 (d, $J=6.8$ Hz, 1H, H-1'); 6.11 (dd, $J=6.8$ and 3.1 Hz, 1H, H-2'); 5.69 (m; 1H, H-4'); 4.32 (dd, $J=11.2$ and 8.2 Hz, 1H, H-5'); 4.28 (dd, $J=11.2$ and 8.2 Hz, 1H, H-5').

The signals were assigned with the aid of a $^1\text{H}, ^1\text{H}$ -COSY spectrum.

30 **^{13}C NMR** : δ (ppm) = 165.23 (CO-4'); 165.17 (CO-3'); 164.88 (CO-2'); 152.85 (C-2); 151.51 (C-9); 149.16 (C-6); 136.62 (C-4); 133.50 (C-p-benz.-4'); 133.35 (C-p-benz.-3'); 133.32 (C-p-benz.-2'); 130.44 (C-11); 129.79 (2*C-o-benz.-4'); 129.78 (2*C-o-benz.-3'); 129.73 (2*C-o-benz.-2'); 129.37 (C-i-benz.-4'); 129.11 (C-i-benz.-3'); 128.78 (C-i-benz.-2'); 128.61 (2*C-m-benz.-4'); 128.37 (2*C-m-benz.-3'); 128.24 (2*C-m-benz.-2'); 122.75 (C-5); 120.47 (C-3); 105.97 (C-10); 85.42 (C-1'); 68.57 (2C-2' and 3'); 66.97 (C-4'); 63.85 (C-5').

The signals were assigned with the aid of a ^1H , ^{13}C -COSY spectrum.

NOESY : NOE between H-11 and H-1', H-2' : Proof of linkage of C-1' to N-7

5

MS : Electrospray ionization (ESI) $[\text{MH}^+] = 590$

$\text{C}_{34} \text{H}_{27} \text{N}_3 \text{O}_7$

$M = 589$

10

X-ray structure analysis of crystals of the monomer proved the correct glycosidic linkage after recrystallization from $\text{CH}_2\text{Cl}_2/\text{isohexane}$. The benzoylated monomer showed the required complexing properties (UV, NMR) after treatment with alcoholic nickel(II) chloride hydrate solution (reflux). This result was confirmed by an X-ray structure analysis of the nickel chelate-ribopyranose-pyrazolylpyridine complex (Fig. 5)

15

This showed the replacement of the nucleobase capable of pairing by a strong nitrogen back-bonding ligand. The monomer prepared and protected in this way in the form of the D enantiomer can be converted as described above into the protected p-RNA-phosphoramidite.

5 Patent claims

1. A supramolecular nanosystem which comprises at least one essentially nonhelical oligomer (oligomer A) and one or more, identical or different, essentially nonhelical and mutually nonpairing oligomers with identical or different functional units (oligomer B), wherein oligomer A can undergo specific noncovalent pairing with oligomer B, and oligomer B can be determined through its monomers.
2. A supramolecular nanosystem as claimed in claim 1, wherein oligomer A can form a hairpin loop.
3. A supramolecular nanosystem as claimed in claim 1, wherein the essentially nonhelical oligomer A and B is a pentopyranosyl-nucleic acid.
4. A supramolecular nanosystem as claimed in claim 3, wherein the pentopyranosyl-nucleic acid is selected from a group containing a ribo-, arabino-, lyxo- and/ xylo-pyranosyl-nucleic acid.
5. A supramolecular nanosystem as claimed in claim 3, wherein the pentopyranosyl part of the pentopyranosyl-nucleic acid has the D or L configuration.
6. A supramolecular nanosystem as claimed in claim 3, wherein the length of the nonhelical oligomer A is selected from a group consisting of 10, 100 and 500 monomer units.
7. A supramolecular nanosystem as claimed in claim 3, wherein the length of the nonhelical oligomer B is selected from a group consisting of 4, 8, 15, 25 and 50 monomer units.
8. A supramolecular nanosystem as claimed in claim 3, wherein the pentopyranosyl part of the pentopyranosyl-nucleic acid is present in a

form selected from a group containing a thiophosphate, alkylated phosphate, phosphonate and amide.

- 5 9. A supramolecular nanosystem as claimed in claim 3, wherein the nucleic acid contains a nucleobase.
- 10 10. A supramolecular nanosystem as claimed in claim 9 wherein the nucleobase is selected from a group containing adenosine, guanosine, isoguanosine, cytosine, isocytosine, thymidine, uracil, 2,6-diaminopurine and xanthine.
- 15 11. A supramolecular nanosystem as claimed in claim 3, wherein the nucleobase is replaced by a chelating agent.
- 20 12. A supramolecular nanosystem as claimed in claim 11, wherein the chelating agent is derived from a precursor compound.
- 25 13. A supramolecular nanosystem as claimed in claim 12 wherein the precursor compound is selected from a group containing pyrazolylpyridine and pyridoquinazoline.
- 30 14. A supramolecular nanosystem as claimed in any of claims 1, wherein the functional unit is selected from a group containing metal, a metal cluster, a semiconductor compound, a peptide, a redox center, a fluorescent label, a chelating agent and a conducting oligomer.
- 35 15. A supramolecular nanosystem as claimed in claim 14, wherein the metal is a noble metal.
16. A supramolecular nanosystem claimed in claim 15 wherein the noble metal is selected from a group containing gold, silver and platinum.
17. A supramolecular nanosystem as claimed in claim 14, wherein the semiconductor is selected from a group containing cadmium selenide and cadmium sulfide.
18. A supramolecular nanosystem as claimed in claim 14, wherein the fluorescent label is selected from a group containing a fluorophore and a chromophore.

19. A supramolecular nanosystem as claimed in claim 14, wherein the chelating agent is derived from a precursor compound.
- 5 20. A supramolecular nanosystem as claimed in claim 19 wherein the precursor compound is selected from a group containing anthocyanins, polyoxycarboxylic acids, polyamines, dimethylglyoxime, ethylenediaminetetraacetic acid and/or nitrilotriacetic acid.
- 10 21. A supramolecular nanosystem as claimed in claim 1, wherein oligomer A is linked to oligomer B.
22. A library comprising a plurality of different supramolecular nanosystems as claimed in claim 1.
- 15 23. A process for preparing a supramolecular nanosystem as claimed in claim 1 or a library as claimed in claim 22, which comprises specific noncovalent pairing of oligomer A with one or more identical or different oligomers B under suitable conditions.
- 20 24. The process as claimed in claim 23, wherein oligomer A is linked to oligomer(s) B in a further step.
- 25 25. A process for structural changing of the supramolecular nanosystem as claimed claim 1, which comprises changing the equilibrium conditions.
- 30 26. The process as claimed in claim 25, wherein the equilibrium conditions are changed by means selected from a group containing changing concentration of oligomer B, changing salt concentration, changing pH, changing pressure and changing temperature.
- 35 27. The use of a supramolecular nanosystem as claimed in claim 1 as electronic component; catalyst; semiconductor; photochemical unit; biocompatible material or unit or functional microprosthesis.
28. The use of a library as claimed in claim 22 for finding a metal catalyst.


Abstract

The present invention relates to a supramolecular nanosystem which comprises at least one essentially nonhelical oligomer (oligomer A) and one or more, identical or different, essentially nonhelical and mutually nonpairing oligomers with identical or different functional units (oligomer B),
5 where oligomer A can undergo specific noncovalent pairing with oligomer B, and oligomer B can be determined through its monomers.


00015678-0016599


Fig. 1

NATURAL BASE PAIRING IN PEPTIDE SYNTHESIS

***Fig. 2***

ENCODED UNITS X1, X2, X3 etc. (E.G. METAL CLUSTER CHROMOPHORES, METALS, METAL IONS)



***Fig. 3***



**Fig. 4**

Fig. 5



COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

As below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below, I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Nonhelical supramolecular nanosystems

the specification of which

- is attached hereto
- was filed on December 10, 1997 as International Patent Application PCT/EP97/06907 and including all the amendments through the date hereof.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s) for which Priority is Claimed:

Federal Republic of Germany, 19651560.2 of December 11, 1996

And I hereby appoint

William F. Lawrence, Registration No. 28,029, of the firm FROMMER LAWRENCE & HAUG, LLP whose post office address is 745 Fifth Avenue, New York, New York 10151, or their duly appointed associate, my attorneys, with full power of substitution and revocation, to prosecute this application, to make alterations and amendments therein, to file continuation and divisional applications thereof, to receive the Patent, and to transact all business in the Patent and Trademark Office and in the Courts in connection therewith, and specify that all communications about the application are to be directed to the following correspondence address:

William F. Lawrence, Esq.
c/o FROMMER LAWRENCE & HAUG, LLP
745 Fifth Avenue
New York, New York 10151

Direct all telephone calls
 to: (212) 588-0800, to the
 attention of:

William F. Lawrence

09319678 081599

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

INVENTOR(S) / Residence

1) Prof. Dr. Albert ESCHENMOSER, Bergstraße 9, 8700 Küsnacht, Switzerland CH

Signature: Date: 24.7.95

2) Dr. Christian MICULKA, Gebeschußstraße 36, 65929 Frankfurt, Germany DE

Signature: Date: 12.7.95

3) Dr. Norbert WINDHAB, Akazienstraße 28, 65795 Hattersheim, Germany DE

Signature: Date: 25.6.99

4) Dr. Hans-Ulrich HOPPE, Amselweg 11, 65929 Frankfurt, Germany DE

Signature: Date: 29.6.99

Citizenship : 1) Swiss, 2) Austrian, 3) - 4) German

Post Office Address of all Inventors:

Bardehle et al.
Galileiplatz 1
D-81679 München
Germany

09319678-081699
65929-8700